

1 **Effect of home-based, overground robotic-assisted gait training on vascular health in**  
2 **people with chronic stroke**

3  
4 James Faulkner<sup>1</sup>, Amy Wright<sup>1, 2</sup>, Keeron Stone<sup>3</sup>, Simon Fryer<sup>4</sup>, Louis Martinelli<sup>5</sup>, Danielle  
5 Lambrick<sup>6</sup>, Eloise Paine<sup>1</sup>, Lee Stoner<sup>7</sup>

- 6  
7 1. Department of Sport, Exercise & Health, University of Winchester, Winchester, UK.  
8 2. School of Sport, Health and Exercise Science, University of Portsmouth, Portsmouth,  
9 UK.  
10 3. School of Sport and Health Sciences, Cardiff Metropolitan University, Cardiff, UK  
11 4. School of Sport & Exercise, University of Gloucestershire, Gloucester, UK.  
12 5. Hobbs Rehabilitation, Martyr Worthy, Winchester, UK.  
13 6. Faculty of Health Sciences, University of Southampton, Southampton, UK.  
14 7. School of Sport & Exercise, University of North Carolina, Chapel Hill, USA.

15  
16 **Corresponding Author:** Professor James Faulkner, School of Sport, Health and Community,  
17 University of Winchester, Winchester, UK, SO22 4NR.

18 Email: James.Faulkner@winchester.ac.uk

19  
20  
21  
22 **Word count:** 3867

23 **Tables:** 2

24 **Supplementary Tables:** 2

25 **Figures:** 1

26  
27  
28 **Keywords:** Rehabilitation, physical activity, exercise, Pulse wave velocity, PWV, robotics  
29  
30  
31  
32  
33  
34  
35  
36

37 **Abstract**

38 Overground robotic-assisted gait training (O-RAGT) has been shown to improve clinical  
39 functional outcomes in people living with stroke. The purpose of this study was to identify  
40 whether a home-based O-RAGT program, in combination with usual care physiotherapy,  
41 would demonstrate improvements in vascular health in individuals with chronic stroke, and,  
42 whether any changes in vascular outcomes would be sustained 3 months after completing the  
43 program. Thirty-four participants with chronic stroke (between 3 months and 5 years post-  
44 stroke) were randomized to either a 10-week O-RAGT program in combination with usual care  
45 physiotherapy, or to a usual care physiotherapy only control group. Participants' pulse wave  
46 analysis (PWA), and regional (carotid-femoral pulse wave analysis [cfPWV]) and local  
47 (carotid) measures of arterial stiffness were assessed at baseline, post-intervention, and 3-  
48 month post-intervention. Analysis of covariance demonstrated a significant reduction  
49 (improvement) in cfPWV between BL and PI for O-RAGT ( $8.81 \pm 2.51$  vs  $7.92 \pm 2.17$  m/s,  
50 respectively), whilst the control group remained unchanged ( $9.87 \pm 2.46$  vs  $9.84 \pm 1.76$  m/s,  
51 respectively;  $p < 0.05$ ;  $\eta^2 = 0.14$ ). The improvement in cfPWV was maintained 3 months after  
52 completing the O-RAGT program. There were no significant Condition by Time interactions  
53 for all PWA and carotid arterial stiffness measures ( $p > 0.05$ ). A significant increase in physical  
54 activity, as determined by the time spent stepping, was observed for O-RAGT between  
55 baseline and post-intervention assessments ( $3.2 \pm 3.0$  to  $5.2 \pm 3.3$  %, respectively) but not for  
56 CON ( $p < 0.05$ ). The improvement in cfPWV, in combination with an increase in physical  
57 activity whilst wearing the O-RAGT and concomitant reduction in sedentary behaviour, are  
58 important positive findings when considering the application of this technology for 'at home'  
59 rehabilitation therapy for stroke survivors. Further research is needed to determine whether  
60 implementing 'at home' O-RAGT programs should be a part of the stroke treatment pathway.  
61 Clinical trial registration number; NCT03104127;  
62 <https://clinicaltrials.gov/ct2/show/NCT03104127>

63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73

74 **Introduction**

75 Globally, stroke is the second leading cause of mortality and lost disability adjusted life years  
76 (WHO., 2018). Stroke recurrence and mortality are impacted by several modifiable risk factors,  
77 and as such are amenable to secondary prevention strategies (Singh et al., 2018). Physical  
78 activity (PA) and exercise and are efficacious modifiable risk factors that are widely  
79 encouraged in stroke survivors as they have been shown to improve physical fitness (oxygen  
80 uptake; 95% confidence interval (CI) 2.98 to 3.83 mL.kg.min<sup>-1</sup> higher), enhance aspects of  
81 physical function (3 m timed-up-and-go test; 95%CI 2.05 to 4.78s faster) (Billinger et al., 2014,  
82 Saunders et al., 2020), as well as reduce recurrent stroke (Hou et al., 2021) and  
83 cardiovascular disease risk (Ivey et al., 2007). Recovering the ability to walk following a stroke  
84 is also a priority in this population (Billinger et al., 2014). For people living with stroke who  
85 have functional limitations, robotic-assisted gait training has been shown to improve walking  
86 capacity, walking speed and motor performance (Cho et al., 2018).

87

88 Over-ground robotic-assisted gait training devices (O-RAGT) allow the patient to walk in a  
89 real-world environment, enabling substantial kinematic variability while ensuring successful  
90 task execution (Duschau-Wicke et al., 2010). The home-based use of O-RAGT may contribute  
91 to the formation of habits that lead to long-term behaviour change as people are able to use  
92 such devices in a familiar context (Gardner et al., 2012). Previous research from our laboratory  
93 found clinically meaningful improvements in functional outcomes (i.e., 6-minute walk test,  
94 balance) after a 10-week daily, home-based, rehabilitation program using O-RAGT, in the form  
95 of a wearable robotic knee orthosis in chronic stroke patients (Wright et al., 2021).  
96 Furthermore, there was an increase in PA (steps taken) on completion of the O-RAGT which  
97 was maintained for a further 3 months after completion of the O-RAGT program. Whilst it is  
98 known that O-RAGT led to sustained improvements in PA and physical function (Wright et al.,  
99 2021), it is unknown whether it also leads to sustained improvements in markers of  
100 cardiovascular health, including blood pressure and arterial stiffness (9). This is important  
101 considering that arterial stiffness is a strong independent risk factor for cardiovascular disease  
102 (Tanaka, 2017).

103

104 Elevated brachial blood pressure, an important risk factor for stroke (Virani et al., 2021), is  
105 widely cited as a marker that needs to be controlled post-stroke by pharmacological and  
106 lifestyle management (Jauch et al., 2013), which could include the engagement in exercise  
107 interventions (Lawrence et al., 2015). However, central haemodynamic components such as  
108 aortic arterial stiffness are better predictors of vascular disease than brachial blood pressure  
109 (Roman et al., 2007). This is because measures of arterial stiffness, such as pulse wave  
110 velocity (PWV), integrate the damage of risk factors on the arterial wall over a long period,

111 whereas traditional risk factors, including blood pressure, hyperglycaemia and dyslipidaemia,  
112 can acutely fluctuate (Klingelhöfer and Sander, 1997). As the aortic walls stiffen, PWV  
113 increases which causes a rise in central systolic pressure and a widening of aortic pulse  
114 pressure (Gąsecki et al., 2012). In ischemic stroke, low aortic stiffness, as measured by  
115 carotid-femoral PWV (cfPWV) is associated with early favorable outcome, independently of  
116 other known prognostic factors (Gąsecki et al., 2012). However, whether a walking-based O-  
117 RAGT program elicits favourable changes in aortic arterial stiffness in people with chronic  
118 stroke is unknown.

119

120 The purpose of this study was to identify whether: i) a home-based O-RAGT program, in  
121 combination with usual care physiotherapy, would demonstrate improvements in  
122 cardiovascular health (e.g., cfPWV, blood pressure) in individuals with chronic stroke, and, ii)  
123 any changes in cardiovascular health outcomes would be sustained for 3 months. It was  
124 hypothesized that regular participation in a 10-week O-RAGT program would improve vascular  
125 health in individuals living with stroke.

126

## 127 **Materials and Methods**

128 This study was a parallel group, randomized controlled clinical trial, reported in accordance  
129 with Consolidated Standards of Reporting Trials (CONSORT) guidelines (Schulz et al., 2010).  
130 The study protocol received institutional human research ethics approval and was registered  
131 with Clinical Trials.gov Protocol Registration and Results System (NCT03104127;  
132 <https://clinicaltrials.gov/ct2/show/NCT03104127>).

133

### 134 *Participants*

135 Participants with chronic stroke (>3 months since stroke diagnosis) were recruited from a  
136 single neuro-physiotherapy practice (Hobbs Rehabilitation, Winchester, UK). All participants  
137 were diagnosed with stroke by a specialist neurologist/stroke consultant from a UK National  
138 Health Service Trust and had completed rehabilitation activities (i.e., inpatient and outpatient)  
139 in accordance with recommended guidelines (Rudd et al., 2017). Written informed consent  
140 was obtained from all participants prior to the commencement of the study.

141

142 Inclusion criteria included: Individuals between 3 months and 5 years post-stroke, who were  
143 living in the community, medically stable, and cognitively capable, able to stand and step with  
144 an aid or with assistance (defined as a Functional Ambulation Categories between 2 and 5)  
145 (Mehrholz et al., 2007), and who were receiving physiotherapy or attending a community-  
146 based, stroke support group at the time of study enrolment. Exclusion criteria included: body  
147 mass index (BMI)  $\geq 40$  kg/m<sup>2</sup>, major arrhythmias, unresolved deep vein thrombosis, recent

148 fractures of the symptomatic limb, open wounds, severe osteoporosis, and/or individuals who  
149 were non-weight bearing.

150

### 151 *Experimental design*

152 Participants were tested between 07:00 and 10:00 am in the physiology laboratory at the  
153 University of Winchester. Participants refrained from intense physical activity for 24 h prior to  
154 testing, and could only consume water for the 12 h before testing. Following an initial  
155 Functional Ambulation Classification and Modified Rankin Scale assessment to provide an  
156 indication of the degree of disability, participants lay supine for 15 minutes. Thereafter, pulse  
157 wave analysis (PWA), and regional (cfPWV) and local (common carotid) measures of arterial  
158 stiffness were assessed. Participants were randomized using covariate adaptive  
159 randomization (Suresh, 2011) to either a 10-week home-based O-RAGT program, which  
160 included weekly 'usual care' physiotherapy, or to a 10-week 'usual care' physiotherapy only  
161 program (CON). Randomization involved sequentially assigning participants to O-RAGT or  
162 control by taking into account their age (age  $\geq 70$  years vs  $< 70$  years), systolic blood pressure  
163 (SBP  $\geq 160$  versus  $< 160$  mmHg) and time since stroke ( $< 12$  months versus  $\geq 12$  months).  
164 Identical assessments were completed at baseline, post intervention (PI) and 3-months post-  
165 intervention (3PI). Participants and researchers collecting outcome data were aware of the  
166 allocated treatment condition, however, data analysts were blinded to the allocation.

167

### 168 *Outcome measures*

#### 169 *Pulse wave velocity (PWV)*

170 The SphygmoCor XCEL device enables simultaneous assessment of proximal and distal  
171 arterial waveforms using a tonometer and volume-displacement cuff, respectively, to  
172 determine arterial pulse transit time. Carotid–femoral pulse transit time was measured as the  
173 time between diastolic feet of the proximal (tonometer) and distal (cuff) arterial pulse  
174 waveforms (Stone et al., 2019). PWV was calculated by dividing pulse transit time by arterial  
175 path length, or PWV distance. For cfPWV, the tonometer was placed on the left carotid artery  
176 and the oscillometric cuff on the left thigh at the level of the femoral artery. The carotid–femoral  
177 was estimated by measuring the linear distance from the suprasternal notch to the top of the  
178 cuff at the centre line of the leg and subtracting the distance from the suprasternal notch to  
179 the carotid artery. Accordingly, cfPWV was calculated as: cfPWV = carotid-femoral  
180 distance/carotid-femoral pulse transit time. Two measurements were taken, but if a difference  
181 of  $> 0.5$  m·s was recorded, a third measure was completed and an average taken of the closest  
182 two.

183

#### 184 *Pulse wave analysis (PWA)*

185 For PWA, oscillometric pressure waveforms were recorded on the left upper arm by a single  
186 observer using the SphygmoCor XCEL device (AtCor Medical, Sydney, Australia), following  
187 standard manufacturer guidelines (Stoner et al., 2013). Each single measurement cycle  
188 consisted of a 60 s brachial blood pressure recording followed by a 10 s sub-systolic recording.  
189 A corresponding aortic pressure waveform was then generated using a validated transfer  
190 function (Butlin et al., 2012), from which central systolic blood pressure (cSBP), augmentation  
191 index (AIx) and augmentation pressure, were derived. Peripheral blood pressures and mean  
192 arterial pressure were also measured. Two measurements were taken, but if a difference of >  
193 5 mmHg in peripheral blood pressure and a difference of > 4% for AIx was recorded (as per  
194 manufacturer guidelines), a third measure was completed and an average taken of the closest  
195 two. Measurements were taken at heart level to ensure no changes in AIx were found due to  
196 alterations in arm angle. Augmentation index was normalized to a heart rate of 75  
197 bpm (AIx75).

198

#### 199 *Common carotid arterial stiffness*

200 A trained ultrasound operator with extensive experience (>10 years) collected all common  
201 carotid arterial stiffness measurements using a portable uSmart 3300 Ultrasound system  
202 (Terason, USA) equipped with a 13-6 MHz bandwidth transducer that provided high resolution  
203 brightness mode measurements. The left common carotid artery of the participants was  
204 examined, in a supine position, and with their head tilted at 45° (angled to the right) on  
205 completion of PWA and PWV measurements. The left common carotid artery was assessed  
206 1-2 cm beneath the bifurcation (Paini et al., 2006). Magnification and focal zone settings were  
207 adjusted to optimize the image of the proximal and distal vessel walls, while ultrasound global  
208 (e.g., acoustic output, gain, dynamic range, gamma and rejection) and probe-dependent (e.g.,  
209 zoom factor, edge enhancement, frame averaging and target frame rate) settings were  
210 standardized (Stoner et al., 2011). Three 10 s video recordings, captured at 30 frames·s, were  
211 obtained during which participants were asked to hold their breath. Videos were recorded  
212 using external video capturing software (LiteCam HD, Englewood Cliffs, NJ, USA). The video  
213 clips were analyzed offline using automated edge-detecting software (FMD Studio, Quipu,  
214 Italy). Custom written Excel Visual Basic code was used to fit peaks and troughs to the  
215 diameter waveforms in order to calculate measures of arterial stiffness, compliance and  
216 distensibility.

217

#### 218 *Accelerometry*

219 Participants wore an ActivPAL3™ device (PAL Technologies Ltd., Glasgow, Scotland) for  
220 seven consecutive days and nights at baseline, PI and 3PI. The ActivPAL3 device was  
221 wrapped in a protective Tegaderm™ (3M, St Paul, USA) and attached to the anterior aspect

222 of the upper third of the thigh, on the asymptomatic side. The ActivPAL3 provided a daily  
223 measure of the: (1) percentage of time spent sitting or lying, (2) percentage of time spent  
224 standing, (3) percentage of time spent stepping, and (4) step counts.

225

#### 226 *O-RAGT device*

227 The O-RAGT device (Alter-G, Bionic Leg orthosis, Fremont, CA, USA) is a battery-operated,  
228 externally-wearable, dynamic device worn by stroke patients during rehabilitation. The device  
229 provides sensory inputs (i.e., auditory and sensory feedback), mobility assistance for users  
230 with reduced lower-limb function, and is fitted and worn in a manner similar to an orthopedic  
231 knee brace. The orthosis shell functions as the user interface that transfers the assistive torque  
232 to the human body, while an actuation unit assists the movement of the limb.

233

#### 234 *O-RAGT program*

235 Participants were familiarized with the O-RAGT device before commencing the 10-week  
236 home-based program. Participants were encouraged to undertake at least 30 minutes per day  
237 of continuous or non-continuous bouts of walking and sit-to-stand exercises, at a moderate  
238 ratings of perceived of exertion (RPE 12-13). There was no maximum daily wear-time. O-  
239 RAGT settings associated with a participant's weight, assistance, resistance, threshold and  
240 knee extension angle settings were individualized and re-assessed every two weeks.  
241 Participants reported their number of steps, duration of use, activities undertaken and RPE for  
242 each day of activity. During this time, participants also continued their 'usual care'.

243

#### 244 *Usual care physiotherapy*

245 Participants in both the control group and O-RAGT program undertook one-to-one, 'usual  
246 care' physiotherapy sessions for the duration of the study. This included stretching and muscle  
247 strengthening exercises, functional movement activities (e.g., walking, step-ups, sit-to-stand)  
248 and soft-tissue massage. There were also group therapy activities which were based on the  
249 same principles but with less therapist engagement. For the duration of the 10-week program  
250 participants were advised to engage in at least 30 minutes of physical activity each day,  
251 undertaking similar functional movement patterns as those reported above.

252

#### 253 *Data analysis*

254 Demographical and clinical comparisons between Conditions (O-RAGT, CON) was  
255 undertaken at baseline with independent sample t-tests (e.g., age, time since stroke,  
256 Functional Ambulation Classification, Modified Rankin Scale, PWA, cfPWV and carotid arterial  
257 stiffness outcomes) and chi-square tests (e.g., sex, stroke diagnosis), as appropriate.

258

259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295

To assess the effect of the O-RAGT intervention on the aforementioned regional and local hemodynamic properties, mixed model, two-factor analysis of covariance (ANCOVA), Condition (O-RAGT, control) x Time (BL, PI, 3PI), adjusted for baseline measures and age, were used to assess all PWA, cfPWV, carotid arterial stiffness and accelerometry outcomes. For PWV analysis, Mean Arterial Pressure was also used as a covariate. Partial eta squared ( $\eta^2$ ) was used to demonstrate the strength of the effect of exercise on the various outcome measures with .0099, .0588 and .1379 representing a small, medium and large effect, respectively (Cohen, 1992). Alpha was set at 0.05. Statistical analyses were performed using Statistical Package for Social Sciences version 26 (SPSS, Inc., Chicago, IL, USA). All data are reported as means (s.d.), unless otherwise specified.

## Results

Participant recruitment and retention are presented in Figure 1. The 31 participants who attended all three assessments (BL, PI, 3PI) were generally older males who had been living with stroke for between 1 and 5 years (Table 1). For O-RAGT, there was an increase in daily wear time ( $50 \pm 20$  min to  $72 \pm 41$  mins) and steps taken with the robotic device ( $887 \pm 520$  to  $945 \pm 542$  steps), and decreases in RPE ( $12.8 \pm 2.2$  to  $10.4 \pm 3.2$ ), from the first to the last week of the O-RAGT intervention, respectively. There were no adverse events whilst participants wore the O-RAGT device.

There were no differences at BL between Conditions for all outcomes except for cfPWV (Table 2). ANCOVA demonstrated a significant Condition by Time interaction for cfPWV ( $p < 0.05$ ; Partial  $\eta^2 = 0.224$ ; Table 2). The O-RAGT group demonstrated a significant reduction (improvement) in cfPWV between BL and PI, whilst the CON was unchanged. The improvement in cfPWV was maintained at 3PI for O-RAGT. There were no significant Condition by Time interactions for all other PWA or arterial stiffness outcomes ( $p > 0.05$ ; Table 2, Supplementary Table A).

For the accelerometry outcomes, a significant Condition by Time interaction was observed for the time spent stepping ( $p < 0.05$ ; Supplementary Table B). The O-RAGT group demonstrated a significant increase in time spent stepping between BL and PI. There were no significant Condition by Time interactions for all other accelerometry outcomes ( $p > 0.05$ ; Supplementary Table B).



296 **Discussion**

297 This study demonstrated improvements in cfPWV in chronic stroke survivors following a  
298 combination of daily, home-based O-RAGT, in the form of a wearable robotic knee orthosis,  
299 and usual care physiotherapy. The improvement in cfPWV which was observed on completion  
300 of the 10 week program was maintained three-months post-intervention (3PI). The  
301 improvement in cfPWV, in combination with an increase in wear-time and physical activity  
302 whilst wearing the O-RAGT, are important positive findings when considering the application  
303 of this technology for 'at home' rehabilitation therapy for stroke survivors.

304

305 *Short-term effect of O-RAGT (baseline to post-intervention)*

306 Carotid-femoral PWV predicts mortality in patients with essential hypertension (Blacher et al.,  
307 1999) and is a strong predictor of cardiovascular disease in a range of clinical populations  
308 (Dahle et al., 2015). Past research has shown significant improvements in cfPWV following  
309 12 weeks of supervised aerobic or resistance training in patient populations when compared  
310 to usual care (Greenwood et al., 2015). Our study demonstrated that cfPWV decreased by,  
311 on average, 0.91 m/s (~12%) in the O-RAGT group at PI, compared to a 0.12 m/s (~1%) in  
312 the control group. This is highly encouraging as a 1m/s reduction in cfPWV is the minimal  
313 clinically important difference, and is strongly associated with decreased cardiovascular  
314 disease risk (Dahle et al., 2015). Although O-RAGT did not quite elicit this minimal clinically  
315 important difference, the statistically significant interaction and the large effect size ( $\eta^2=$   
316 0.135) indicates a robust and promising impact on regional arterial stiffness.

317

318 In the present study there were no statistical changes in central haemodynamic (PWA) or local  
319 carotid arterial stiffness parameters (Table 2; Supplementary Table A). Past research has  
320 demonstrated that aerobic training interventions typically elicit reductions in SBP (95% CI) of  
321 up to 5.0 mmHg (Halbert et al., 1997), while during a large-scale analysis of randomised trials,  
322 a 5mmHg reduction of SBP following pharmacological treatment reduced the risk of major  
323 cardiovascular events by ~10% (Rahimi et al., 2021). Accordingly, although not statistically  
324 significant, the ~6 mmHg reduction in SBP and cSBP for O-RAGT participants is comparable  
325 with prior literature and highly encouraging given the limited mobility of the population and the  
326 low-intensity O-RAGT intervention implemented. It is notable that unlike cfPWV, local carotid  
327 artery stiffness did not change in response to O-RAGT, but this is perhaps not surprising given  
328 that regional measures of arterial stiffness summate a larger portion of the arterial tree (e.g.,  
329 cfPWV) and therefore may better detect the impact of cardiovascular disease risk factors (i.e.  
330 blood pressure and physical activity). Further, it is well recognized that regional and local  
331 measures of arterial stiffness are not always closely associated (12). Although not significant,  
332 the average changes in local carotid artery stiffness, compliance and distensibility for O-RAGT

333 participants between BL and PI were -17%, 10% and 16%, respectively. Past research has  
334 shown larger changes in common carotid arterial compliance (17%) and distensibility (22%)  
335 in people with stroke who engaged in a moderate to high intensity exercise program (Woolley  
336 et al., 2015). Woolley et al. (2015) also observed reductions in SBP and DBP of 6% and 12%,  
337 respectively, and stated that as these changes were concomitant with the reduction in carotid  
338 artery stiffness, it may be suggested that reduced blood pressures had greater influence on  
339 local (carotid) arterial stiffness than potential modifications to the elastic properties of the  
340 vessel.

341

#### 342 *Longer-term effect of O-RAGT (post-intervention to 3-month post-intervention)*

343 Long-term outcomes are of utmost importance when evaluating the clinical importance of  
344 interventions. An important characteristic of successful behavior change is that individuals  
345 continue to engage in lifestyle modifications once the stimulus (i.e., use of the O-RAGT device)  
346 has been removed. A recent meta-analysis for stroke patients revealed that end-of-  
347 intervention benefits gained from regular physical fitness training do not persist following  
348 completion of an intervention (Saunders et al., 2020). In non-stroke populations, some  
349 exercise studies have shown that following one-month cessation of an exercise intervention,  
350 PWV values revert back to pre-intervention baseline levels (Van Bortel et al., 2012, O'Halloran  
351 et al., 2014). However, in our study the improvement in cfPWV at PI was maintained at 3PI.  
352 This finding may be underpinned by the fact that the increase in physical activity (e.g., time  
353 spent stepping) observed between BL and PI was sustained between PI and 3PI  
354 (Supplementary Table B). For example, participants undertook an additional ~1,700 steps per  
355 day at the time of the PI assessment compared to BL (~39% improvement), which was  
356 generally maintained at the 3PI assessment. This positive change in habitual activity patterns  
357 may have important practical implications for the adoption of over-ground, lower-limb robotic  
358 technology in the rehabilitation of stroke patients. As we recruited a chronic stroke population,  
359 it will be of interest to see whether similar changes in cfPWV and habitual activity patterns  
360 occur when implementing O-RAGT interventions with acute stroke patients ( $\leq 3$  months), and  
361 whether such devices are beneficial for individuals who do not receive ongoing rehabilitation.

362

363 The encouraging findings surrounding cfPWV is unique as the O-RAGT program focused on  
364 walking, a low-intensity activity, with RPEs of 11 to 13 typically recorded in the activity diaries  
365 (Supplementary Table B). Past research has often shown favourable changes in PWV when  
366 training interventions have prescribed moderate to vigorous volumes of physical activity  
367 (Hasegawa et al., 2018, Kim et al., 2017). However, low-intensity exercise may be more  
368 achievable and sustainable than higher intensity programs as feelings of enjoyment and  
369 wellbeing are strong motives for continued participation (Dishman et al., 1985). Ekkekakis and

370 colleagues' review into the pleasure and displeasure people feel whilst exercising reported  
371 that pleasure is reduced mainly above the ventilatory or lactate threshold, but that pleasant  
372 perceptions are often observed below such threshold intensities (Ekkekakis et al., 2011),  
373 which would likely have been the case in our study. Due to the encouraging findings of the  
374 present study and those associated with functional outcome measures (Wright et al., 2021),  
375 measures of enjoyment during and following robotic technology use at low-intensities of  
376 physical activity should be monitored in both the short- and longer-term (e.g., 12 months PI),  
377 as this type of technology and O-RAGT program could have a substantial impact in aiding the  
378 recovery of chronic stroke survivors.

379

### 380 Strengths and limitations

381 In order to contextualize the present findings, specific limitations must be addressed. Firstly,  
382 the small sample size was determined based on a primary outcome measure which was not  
383 a focus in this study (6-minute walk test) (Wright et al., 2021). However, an a priori sample  
384 size calculation based on the cfPWV reported between groups at PI demonstrated that a  
385 sufficient sample size was recruited (n = 13 per group). Secondly, regional (cfPWV) and local  
386 (carotid) measures of arterial stiffness were only investigated on participants' left-side. As the  
387 stroke diagnosis (and hemisphere affected) varied between participants (Table 1), the  
388 assessment of regional and local stiffness measures on both the right and left-side may have  
389 been informative, particularly for those participants for whom the right carotid artery may have  
390 been symptomatic. Thirdly, participants were recruited from an independent neuro-  
391 physiotherapy practice which could be a determining factor to whether a home-based program  
392 is successful. The selected population were likely to be highly motivated to engage in  
393 rehabilitation due to the costs associated with engaging in physiotherapy with an independent  
394 provider. The total dosage of physical activity in the O-RAGT condition was likely higher than  
395 the control condition and could have also been a reason for the observed findings. Finally,  
396 findings should be interpreted with caution as multiple analyses inflate the risk of type I error,  
397 while researchers responsible for collecting outcome data were not blinded to group allocation.  
398 Strengths to the study included the use of gold-standard non-invasive measures of arterial  
399 stiffness, the inclusion of a 3-month PI assessment, and the implementation of a home-based  
400 exercise program which may have enabled participants to undertake a higher volume of  
401 walking as the participants could wear the O-RAGT device at any time or day during the  
402 program period. The observed increases in habitual physical activity could help prevent  
403 secondary complications associated with cardiovascular disease and future cardio- or  
404 cerebro-vascular events (i.e., reducing strokes) if such programs are implemented over the  
405 longer-term.

406

407 In conclusion, the present study has demonstrated that participation in a 10-week, home-  
408 based, O-RAGT program, in combination with weekly, usual care physiotherapy, can elicit  
409 greater improvements in regional (cfPWV) measures of arterial stiffness in people with stroke  
410 than 'usual care' alone. Importantly, the changes reported in cfPWV were maintained at 3PI  
411 assessment suggesting this may be a sustainable and efficacious treatment option once  
412 access to the O-RAGT device has been removed. Individuals randomized to the O-RAGT  
413 program also demonstrated increases in physical activity which could have the potential to  
414 improve quality of life. However, larger randomized controlled trials are required to identify  
415 whether the use of O-RAGT is appropriate to recommend as a part of usual care, while further  
416 research is also needed to determine whether implementing 'at home' O-RAGT programs  
417 should be a part of the stroke treatment pathway.

418

#### 419 **Conflict of Interest**

420 AlterG Bionic Leg orthoses were provided free of charge by AlterG (Fremont, CA). Alter G  
421 had no input or influence on the data analysis or manuscript preparation. The authors  
422 declare that the research was conducted in the absence of any commercial or financial  
423 relationships that could be construed as a potential conflict of interest.

424

#### 425 **Author contributions**

426 JF and LM conceptualized the study; JF, AW, KS, SF, DL, EP collected the data for the  
427 study; JF and LS were responsible for the formal analysis; JF was responsible for the  
428 original draft preparation; all authors reviewed, edited and approved the final manuscript. All  
429 authors have read and agreed to the published version of the manuscript.

430

#### 431 **Funding**

432 The research study is funded by the University of Winchester (RKE/10/2015-16). AlterG Bionic  
433 Leg orthoses have been provided freely by AlterG (Fremont, CA).

434

#### 435 **Acknowledgements**

436 The authors would like to thank all the people who participated in the trial and to their families.

437

#### 438 **References**

- 439 Billinger S. A., Arena R., Bernhardt J., Eng J. J., Franklin B. A., Johnson C. M. et al. 2014.  
440 Physical activity and exercise recommendations for stroke survivors: a statement for  
441 healthcare professionals from the American Heart Association/American Stroke  
442 Association. *Stroke*, 45, 2532-53.  
443 Blacher J., Asmar R., Djane S., London G. M., Safar M. E. 1999. Aortic pulse wave velocity  
444 as a marker of cardiovascular risk in hypertensive patients. *Hypertension*, 33, 1111-7.

- 445 Butlin M., Qasem A., Avolio A. P. 2012. Estimation of central aortic pressure waveform  
446 features derived from the brachial cuff volume displacement waveform. *Annu Int Conf*  
447 *IEEE Eng Med Biol Soc*, 2012, 2591-4.
- 448 Cho J. E., Yoo J. S., Kim K. E., Cho S. T., Jang W. S., Cho, K. H. et al. 2018. Systematic  
449 Review of Appropriate Robotic Intervention for Gait Function in Subacute Stroke  
450 Patients. *Biomed Res Int*, 2018, 4085298.
- 451 Cohen J. 1992. A power primer. *Psychological Bulletin*, 112, 155–159.
- 452 Dahle D. O., Eide I. A., Åsberg A., Leivestad T., Holdaas H., Jenssen T. G. et al. 2015. Aortic  
453 Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients.  
454 *Transplantation*, 99, 1730-7.
- 455 Dishman R. K., Sallis J. F., Orenstein D. R. 1985. The determinants of physical activity and  
456 exercise. *Public Health Rep*, 100, 158-71.
- 457 Duschau-Wicke A., Caprez A., Riener R. 2010. Patient-cooperative control increases active  
458 participation of individuals with SCI during robot-aided gait training. *Journal of*  
459 *NeuroEngineering and Rehabilitation*, 7, 43.
- 460 Ekkekakis P., Parfitt G., Petruzzello S. J. 2011. The Pleasure and Displeasure People Feel  
461 When they Exercise at Different Intensities. *Sports Medicine*, 41, 641-671.
- 462 Gardner B., Lally P., Wardle J. 2012. Making health habitual: the psychology of 'habit-  
463 formation' and general practice. *British Journal of General Practice*, 62, 664-6.
- 464 Gasecki D., Rojek A., Kwarciany M., Kowalzyk K., Boutouyrie P., Nyka W. et al. 2012. Pulse  
465 wave velocity is associated with early clinical outcome after ischemic stroke.  
466 *Atherosclerosis*, 225, 348-352.
- 467 Greenwood S. A., Koufaki P., Mercer T. H., Rush R., O'Connor E., Tuffnell R. et al. 2015.  
468 Aerobic or Resistance Training and Pulse Wave Velocity in Kidney Transplant  
469 Recipients: A 12-Week Pilot Randomized Controlled Trial (the Exercise in Renal  
470 Transplant [ExeRT] Trial). *American Journal of Kidney Disease*, 66, 689-98.
- 471 Halbert J. A., Silagy C. A., Finucane P., Withers R. T., Hamdorf P. A., Andrews G. R. 1997.  
472 The effectiveness of exercise training in lowering blood pressure: a meta-analysis of  
473 randomised controlled trials of 4 weeks or longer. *Journal of Human Hypertension*, 11,  
474 641-649.
- 475 Hasegawa N., Fujie S., Horii N., Miyamoto-Mikami E., Tsuji K., Uchida M. et al. 2018. Effects  
476 of Different Exercise Modes on Arterial Stiffness and Nitric Oxide Synthesis. *Medicine*  
477 *and Science in Sports and Exercise*, 50, 1177-1185.
- 478 Hou L., Li M., Wang J., Li Y., Zheng Q., Zhang L. et al. 2021. Association between physical  
479 exercise and stroke recurrence among first-ever ischemic stroke survivors. *Science*  
480 *Reports*, 11, 1-9.
- 481 Ivey F. M., Ryan A. S., Hafer-Macko C. E., Goldberg A. P., Macko R. F. J. S. 2007. Treadmill  
482 aerobic training improves glucose tolerance and indices of insulin sensitivity in  
483 disabled stroke survivors: a preliminary report. *Stroke*, 38, 2752-2758.
- 484 Jauch E. C., Saver J. L., Adams H. P., Bruni A., Connors J. J., Demaerschalk B. M. et al.  
485 2013. Guidelines for the early management of patients with acute ischemic stroke: a  
486 guideline for healthcare professionals from the American Heart Association/American  
487 Stroke Association. *Stroke*, 44, 870-947.
- 488 Kim H.-K., Hwang C.-L., Yoo J.-K., Hwang M.-H., Handberg E. M., Petersen J. W. et al. 2017.  
489 All-extremity exercise training improves arterial stiffness in older adults. *Medicine and*  
490 *Science in Sports and Exercise*, 49, 1404.
- 491 Klingelhofer J., Sander D. 1997. Cardiovascular consequences of clinical stroke. *Bailliere's*  
492 *clinical neurology*, 6, 309-335.
- 493 Lawrence M., Pringle J., Kerr S., Booth J., Govan L., Roberts N. J. 2015. Multimodal  
494 secondary prevention behavioral interventions for TIA and stroke: a systematic review  
495 and meta-analysis. *PLoS One*, 10, e0120902.
- 496 Mehrholz J., Wagner K., Rutte K., Meissner D., Pohl M. 2007. Predictive validity and  
497 responsiveness of the functional ambulation category in hemiparetic patients after  
498 stroke. *Archives of Physical Medicine and Rehabilitation*, 88, 1314-9.

499 O'Halloran P. D., Blackstock F., Shields N., Holland A., Iles R., Kingsley M. et al. 2014.  
500 Motivational interviewing to increase physical activity in people with chronic health  
501 conditions: a systematic review and meta-analysis. *Clinical Rehabilitation*, 28, 1159-  
502 71.

503 Paini A., Boutouyrie P., Calvet D., Tropeano A. I., Laloux B., Laurent S. 2006. Carotid and  
504 aortic stiffness: determinants of discrepancies. *Hypertension*, 47, 371-6.

505 Rahimi K., Bidel Z., Nazarzadeh M., Copland E., Canoy D., Ramakrishnan R. et al. 2021.  
506 Pharmacological blood pressure lowering for primary and secondary prevention of  
507 cardiovascular disease across different levels of blood pressure: an individual  
508 participant-level data meta-analysis. *The Lancet*, 397, 1625-1636.

509 Roman M. J., Devereux R. B., Kizer J. R., Lee E. T., Galloway J. M., Ali T. et al. 2007. Central  
510 pressure more strongly relates to vascular disease and outcome than does brachial  
511 pressure: the Strong Heart Study. *Hypertension*, 50, 197-203.

512 Rudd A. G., Bowen A., Young G. R., James M. A. 2017. The latest national clinical guideline  
513 for stroke. *Clin Med (Lond)*, 17, 154-155.

514 Saunders D. H., Sanderson M., Hayes S., Johnson L., Kramer S., Carter D. et al. 2020.  
515 Physical fitness training for stroke patients. *Cochrane Database Systematic Reviews*,  
516 3, Cd003316.

517 Schulz K. F., Altman D. G., Moher D. 2010. CONSORT 2010 Statement: updated guidelines  
518 for reporting parallel group randomised trials. *British Medical Journal*, 340, c332.

519 SlinghR.-J., Chen S., Ganesh A., Hill M. D. 2018. Long-term neurological, vascular, and  
520 mortality outcomes after stroke. *International Journal of Stroke*, 13, 787-796.

521 Stone K., Fryer S., Kelsch E., Burnet K., Zieff G., Faulkner J. et al. 2019. Validity and reliability  
522 of lower-limb pulse-wave velocity assessments using an oscillometric technique.  
523 *Experimental Physiology*, 104, 765-774.

524 Stoner L., Lambrick D. M., Faulkner J., Young J. 2013. Guidelines for the use of pulse wave  
525 analysis in adults and children. *Journal of Atherosclerosis and Thrombosis*, 20, 404-6.

526 Stoner L., West C., Morozewicz-CATES D., Young J. M. 2011. Optimization of ultrasound  
527 assessments of arterial function. *Open Journal of Clinical Diagnostics*, 1, 7.

528 Suresh K. 2011. An overview of randomization techniques: An unbiased assessment of  
529 outcome in clinical research. *Journal of Human Reproductive Sciences*, 4, 8-11.

530 Tanaka H. 2017. Various Indices of Arterial Stiffness: Are They Closely Related or Distinctly  
531 Different? *Pulse*, 5, 1-6.

532 Van Bortel L. M., Laurent S., Boutouyrie P., Chowienczyk P., Cruickshank J. K., De Backer T.  
533 et al. 2012. Expert consensus document on the measurement of aortic stiffness in daily  
534 practice using carotid-femoral pulse wave velocity. *Journal of Hypertension*, 30, 445-  
535 8.

536 Virani S. S., Alonso A., Aparicio H. J., Benjamin E. J., Bittencourt M. S., Callaway C. et al.  
537 2021. Heart Disease and Stroke Statistics-2021 Update: A Report From the American  
538 Heart Association. *Circulation*, 143, e254-e743.

539 World Health Organisation. 2018. Global health estimates 2016: deaths by cause, age, sex,  
540 by country and by region, 2000-2016. Geneva, World Health Organization 2018  
541 [https://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index1.html](https://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html).

542 Woolley B., Stoner L., Lark S., Wong L., Lanford J., Faulkner J. 2015. Effect of early exercise  
543 engagement on arterial stiffness in patients diagnosed with a transient ischaemic  
544 attack. *Journal of Human Hypertension*, 29, 87-91.

545 Wright A., Stone K., Martinelli L., Fryer S., Smith G., Lambrick D. et al. 2021. Effect of  
546 combined home-based, overground robotic-assisted gait training and usual  
547 physiotherapy on clinical functional outcomes in people with chronic stroke: A  
548 randomized controlled trial. *Clinical Rehabilitation*, 35, 882-893.

549

550

551

552 **Figure Legend**

553 **Figure 1. Consort Statement**

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589 **Table 1.** Participant demographics at baseline

Demographic		O-RAGT		CON		p
		n	%	n	%	
Sex	Male	14	88	13	87	0.945
	Female	2	12	2	13	
Age (years)		59.6 ± 10.1		64.2 ± 10.7		0.228
Stroke diagnosis	Ischemic	15	94	13	87	0.505
	Hemorrhagic	1	6	2	13	
Hemiparetic side	Left	11	69	9	60	0.611
	Right	5	31	6	40	
Orthotic*	Yes	9	56	10	66	0.955
	No	7	44	5	34	
Walking aid**	Yes	14	88	12	80	0.570
	No	2	12	3	20	
Time since stroke (months)		31 ± 19		28 ± 21		0.679
FAC		3.4 ± 1.0		3.3 ± 1.1		0.793
MRS		3.3 ± 0.6		3.4 ± 0.7		0.672

590

591 **Note:** Age, time since stroke, FAC, and MRS are presented as mean ± SD. All other demographics are presented as total number and percentage.

592 **Abbreviations:** CON, Control group; FAC, Functional Ambulation Categories; MRS, Modified Rankin Scale; O-RAGT, Over-ground-Robotic  
 593 Assisted Gait Training.

594 \*Orthotic refers to a soft or hard foot and/or ankle brace; \*\* Walking aid refers to use of a walking stick, tripod or quadripod



595 **Table 2.** PWA, cfPWV and local arterial stiffness outcome measures reported at baseline (BL) and post-intervention (PI, 3PI) for O-RAGT and  
 596 control (CON) conditions

		Assessment			Condition x Time interaction		
		BL	PI	3PI	F	p	$\eta p^2$
<b>SBP (mmHg)</b>	<b>O-RAGT</b>	139 ± 14	133 ± 14	135 ± 13	2.161	0.123	0.061
	<b>CON</b>	142 ± 17	143 ± 21	142 ± 19			
<b>DBP (mmHg)</b>	<b>O-RAGT</b>	83 ± 12	81 ± 11	82 ± 10	0.086	0.917	0.003
	<b>CON</b>	81 ± 9	80 ± 8	81 ± 10			
<b>cSBP (mmHg)</b>	<b>O-RAGT</b>	130 ± 13	125 ± 13	127 ± 12	1.207	0.306	0.040
	<b>CON</b>	130 ± 16	130 ± 18	128 ± 18			
<b>cDBP (mmHg)</b>	<b>O-RAGT</b>	84 ± 11	82 ± 11	82 ± 10	0.356	0.701	0.012
	<b>CON</b>	84 ± 10	81 ± 10	81 ± 9			
<b>cPP (mmHg)</b>	<b>O-RAGT</b>	46 ± 12	44 ± 10	45 ± 11	1.428	0.248	0.047
	<b>CON</b>	48 ± 14	49 ± 15	48 ± 13			
<b>AIx75</b>	<b>O-RAGT</b>	27.8 ± 13.4	24.6 ± 11.5	26.4 ± 12.7	1.169	0.317	0.034
	<b>CON</b>	26.1 ± 8.5	25.1 ± 8.9	24.2 ± 8.7			
<b>MAP (mmHg)</b>	<b>O-RAGT</b>	101 ± 11	97 ± 12	97 ± 10	0.188	0.829	0.005
	<b>CON</b>	99 ± 10	98 ± 11	98 ± 11			
<b>cfPWV (m/s)</b>	<b>O-RAGT</b>	8.81 ± 2.51	7.92 ± 2.17	7.89 ± 2.30	4.261	0.023*	0.135
	<b>CON</b>	9.87 ± 2.46	9.84 ± 1.76	9.87 ± 1.77			
<b>β-stiffness</b>	<b>O-RAGT</b>	10.5 ± 4.9	8.7 ± 3.6	9.3 ± 3.7	1.147	0.325	0.038
	<b>CON</b>	9.0 ± 2.2	9.4 ± 2.2	9.3 ± 3.0			

597 **Abbreviations:** Alx75, Alx at 75 b·min<sup>-1</sup>; BL, Baseline; cfPWV, Carotid-femoral pulse wave velocity; cDBP, Central diastolic blood pressure;  
598 CON, Control; cPP, Central pulse pressure; cSBP, Central systolic blood pressure; DBP, Diastolic blood pressure; MAP, Mean arterial pressure;  
599 O-RAGT, Over-ground robotic-assisted gait training; PI, Post-intervention; SBP, Systolic blood pressure; 3PI, three-month post-intervention  
600 \* Significant Test x Condition interaction (p < 0.05)

601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619